Early-phase oncology trials carry substantial scientific and commercial risk in cancer drug development. Getting them right ...
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
Explore the debate surrounding animal testing as new methods may jeopardise patient safety if not properly validated.
There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...
Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty ...
As China's new drug R&D enters the 'deep waters' of homogeneous competition, the path for followers has become increasingly ...
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development ...
The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.
During the first year of the Trump administration, signs of an anti-mRNA slant within the FDA and HHS became more and more ...
It’s a priority project for Emirates Drug Establishment, which was officially launched at the World Health Expo 2026 ...
The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...
The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results